



Media Release

For Immediate Release

Immunotope and Immunovaccine Announce U.S. Patent for Therapeutic Cancer Vaccine Antigens

Doylestown, PA and Halifax, CANADA; February 23, 2011— Immunotope Inc. and Immunovaccine Inc. (TSX-V:IMV) announced today that the U.S. Patent and Trademark Office has issued an official Notice of Allowance for a new U.S. Patent specific to the DPX-0907 therapeutic cancer vaccine.

The new U.S. patent application titled “Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer” provides additional intellectual property protection in the U.S. for the seven antigens used in Immunovaccine’s DPX-0907, a therapeutic cancer vaccine for patients with breast, ovarian or prostate cancers.

“We are delighted that the U.S. Patent and Trademark Office has recognized the novelty of our cancer antigens. The issuance of this patent will enhance the commercial potential of DPX-0907 in the largest market for cancer therapeutics in the world,” commented Dr. Ramila Philip, President and CSO of Immunotope Inc.

“This new patent, in addition to our family of patents relating to our DepoVax™ vaccine delivery platform, provides a very strong intellectual property position for DPX-0907 in the U.S.” said Dr. Marc Mansour, Vice President of R&D at Immunovaccine Inc.

In July 2009, Immunovaccine obtained exclusive worldwide rights to license the seven antigens from Immunotope. These antigens are believed to be present on the surface of breast, ovarian and prostate cancers and part of critical cancer cell processes. For more information on the seven antigens visit www.imvaccine.com/userfiles/file/7CancerAntigens.pdf

Immunovaccine is completing a Phase I clinical trial for DPX-0907 and preliminary results have shown the vaccine to be well tolerated and safe. Immunovaccine has recently completed enrollment for this trial and will be evaluating additional safety and immune response data that will be available in the second quarter of 2011.

About Immunotope Inc.

Immunotope is a clinical stage antigen discovery company, developing immunotherapy products for the treatment of cancer and chronic viral infections. Immunotope focuses on the critical, unmet need to diagnose cancer at its earliest stages and to provide effective treatments that destroy tumors and prevent recurrence and metastasis. www.immunotope.com

About Immunovaccine Inc.

Immunovaccine Inc. (TSX-V:IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery platform and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines. www.imvaccine.com

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company,

including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

-30-

Contact:

Ramila Philip, CSO, Immunotope, Inc.

T: 215 253 4180 E: info@immunotope.com

Jennifer Ayotte, Director Communications, Immunovaccine Inc.

T: (902) 209-4704 E: jayotte@imvaccine.com

Madeleine Desmond, Tiberend Strategic Advisors, Inc.

T: (212) 827-0020 E: mdesmond@tiberend.com